Clinical trial
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris
NCT01017146 is registered in ClinicalTrials.gov with Stiefel, a GSK Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris
- Lead sponsor
- Stiefel, a GSK Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2009
- Completion date
- November 30, 2010
- Enrollment
- 744 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.